Hemant Surgical

Why is Hemant Surgical Industries Ltd falling/rising?

As of 10-Jun, Hemant Surgical Industries Ltd's stock price has risen to Rs 379.50, up 2.85%, driven by recent performance gains and sector outperformance, despite a decline in investor participation. The stock has shown a total return of 5.69% over the last two days.

As of 10-Jun, Hemant Surgical Industries Ltd is experiencing a rise in its stock price, currently at Rs 379.50, reflecting an increase of Rs 10.5 or 2.85%. This upward movement can be attributed to several factors. The stock has outperformed its sector by 3.74% today and has shown a consecutive gain over the last two days, accumulating a total return of 5.69% during this period. Additionally, the stock opened with a gain of 2.17% today and reached an intraday high of Rs 387.45, which is a 5% increase from its previous close.<BR><BR>Despite these positive indicators, it is important to note that there has been a decline in investor participation, with the delivery volume dropping by 53.22% compared to the 5-day average. However, the stock remains liquid enough for trading, based on its average traded value. Overall, the combination of recent performance gains and sector outperformance contributes to the rising stock price of Hemant Surgical Industries Ltd.

What does Hemant Surgical do?

Hemant Surgical Industries Ltd is a micro-cap company in the Healthcare Services sector, specializing in medical equipment and supplies. It was incorporated in 1989 and has a market cap of INR 492 Cr, with key metrics including a P/E ratio of 27.00 and a debt-equity ratio of 0.05.

Overview:<BR>Hemant Surgical Industries Ltd is engaged in the business of Medical Equipment & Supplies within the Healthcare Services industry and operates in the micro-cap market segment.<BR><BR>History:<BR>The company was originally incorporated as "Hemant Surgical Industries Private Limited" on March 27, 1989, and later converted into a public limited company, changing its name to "Hemant Surgical Industries Limited" on February 22, 1994. Revenue and profit data for the latest quarter are not available.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: N/A<BR>Most recent Net Profit: N/A<BR>Market-cap value: INR 492 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: 27.00<BR>Industry P/E: 60<BR>Dividend Yield: 0.00%<BR>Debt-Equity: 0.05<BR>Return on Equity: 14.34%<BR>Price-to-Book: 3.79<BR><BR>Contact Details:<BR>Registrar Address: Not available.

Which are the latest news on Hemant Surgical?

Is Hemant Surgical overvalued or undervalued?

As of December 1, 2025, Hemant Surgical is considered overvalued with a PE ratio of 43.61 and elevated EV ratios compared to peers, despite a strong year-to-date return of 115.49%.

As of 1 December 2025, Hemant Surgical's valuation grade has moved from fair to expensive, indicating a shift towards overvaluation. The company's current PE ratio stands at 43.61, while its EV to EBITDA ratio is 36.83, and the EV to Sales ratio is 3.14. These figures suggest that Hemant Surgical is trading at a premium compared to its earnings and sales, which raises concerns about its valuation.<BR><BR>In comparison to its peers, Hemant Surgical's valuation appears high, especially when juxtaposed with Apollo Hospitals, which has a PE ratio of 62.66 and an EV to EBITDA of 32.97, marking it as attractive. Other competitors like Narayana Hrudaya and Max Healthcare are also valued higher, with PE ratios of 45.9 and 77.91, respectively. Given these comparisons and the elevated ratios, Hemant Surgical is deemed overvalued in the current market context. Notably, the company has outperformed the Sensex with a year-to-date return of 115.49%, but this performance does not mitigate the concerns surrounding its current valuation.

How has been the historical performance of Hemant Surgical?

For the fiscal year ending March 2025, Hemant Surgical reported an operating income of 106.64 crore and a net profit of 8.04 crore, with total assets and liabilities both at 148.15 crore. The company had a cash flow from operating activities of 8.00 crore, resulting in a closing cash balance of 9.00 crore.

Answer:<BR>The historical performance of Hemant Surgical for the year ending March 2025 shows a total operating income of 106.64 crore, with a net profit after tax of 8.04 crore. The company reported an operating profit margin of 8.42% and a profit after tax margin of 7.54%. The earnings per share stood at 7.7, and the book value per share was 60.51. Total liabilities were recorded at 148.15 crore, with total assets also at 148.15 crore, indicating a balanced position. The cash flow from operating activities was 8.00 crore, while the net cash outflow for the period was 3.00 crore, resulting in a closing cash and cash equivalent of 9.00 crore.<BR><BR>Breakdown:<BR>In the fiscal year ending March 2025, Hemant Surgical achieved a total operating income of 106.64 crore, primarily driven by net sales. The company faced raw material costs of 94.26 crore, leading to a total expenditure of 97.66 crore, which resulted in an operating profit (PBDIT) of 14.10 crore. After accounting for interest and depreciation, the profit before tax was reported at 10.47 crore, culminating in a profit after tax of 8.04 crore. The company's total liabilities and total assets were both recorded at 148.15 crore, reflecting a stable financial position. The cash flow analysis indicated a cash flow from operating activities of 8.00 crore, but an overall net cash outflow of 3.00 crore, leaving a closing cash balance of 9.00 crore.

How big is Hemant Surgical?

As of 24th July, Hemant Surgical Industries Ltd has a market capitalization of 209.00 Cr, classifying it as a Micro Cap company, with Shareholder's Funds of 54.86 Cr and Total Assets of 96.64 Cr; however, recent financial data for Net Sales and Net Profit is unavailable.

As of 24th July, <BR><BR>Market Cap: Hemant Surgical Industries Ltd has a market capitalization of 209.00 Cr, categorizing it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: There is no valid financial data available for Net Sales and Net Profit for the latest four quarters.<BR><BR>Balance Sheet Snapshot: The reporting period is March 2024, with Shareholder's Funds amounting to 54.86 Cr and Total Assets valued at 96.64 Cr.

Who are the top shareholders of the Hemant Surgical?

The top shareholders of Hemant Surgical include Hanskumar Shamji Shah with 33.78%, followed by Carnelian Structural Shift Fund at 1.11%, and individual investors holding 20.87%. There are no pledged promoter holdings, and one Foreign Institutional Investor holds 0.39%.

The top shareholders of Hemant Surgical include the promoters, with Hanskumar Shamji Shah holding the largest share at 33.78%. There are no pledged promoter holdings, and the company has one Foreign Institutional Investor (FII) holding 0.39%. The highest public shareholder is Carnelian Structural Shift Fund, which holds 1.11%. Additionally, individual investors collectively hold 20.87% of the shares.

Who are the peers of the Hemant Surgical?

Hemant Surgical's peers include Sastasundar Ven., Prevest Denpro, One Global Serv, Nureca, Bilcare, Take Solutions, Choksi Laborator, Royal Sense, QMS Medical, and Aakaar Medical. In terms of management risk, Hemant Surgical is rated as Good, with its 1-year return at -2.17%, higher than Take Solutions but lower than most peers.

Peers: The peers of Hemant Surgical are Sastasundar Ven., Prevest Denpro, One Global Serv, Nureca, Bilcare, Take Solutions, Choksi Laborator, Royal Sense, QMS Medical, and Aakaar Medical.<BR><BR>Quality Snapshot: Excellent management risk is observed at One Global Serv and Aakaar Medical, while Good management risk is found at Hemant Surgical. Average management risk is present at Prevest Denpro and QMS Medical, and Below Average management risk is noted at Sastasundar Ven., Nureca, Bilcare, Take Solutions, Choksi Laborator, and Royal Sense. Growth is Excellent at One Global Serv and Aakaar Medical, Average at Choksi Laborator, and Below Average at Hemant Surgical, Prevest Denpro, Nureca, Bilcare, Take Solutions, and Royal Sense. Excellent capital structure is seen at Sastasundar Ven., Prevest Denpro, One Global Serv, Nureca, Hemant Surgical, and Royal Sense, while Below Average capital structure is noted at Bilcare, Take Solutions, Choksi Laborator, and QMS Medical.<BR><BR>Return Snapshot: The peer with the highest 1-year return is One Global Serv at 89.49%, while the lowest is Take Solutions at -52.91%. Hemant Surgical's 1-year return is -2.17%, which is higher than Take Solutions but lower than the majority of its peers. Additionally, the six-month return is negative for Nureca, Take Solutions, and Royal Sense.

Who are in the management team of Hemant Surgical?

As of March 2023, the management team of Hemant Surgical includes Hanskumar Shamji Shah (Chairman & Managing Director), Hemant Praful Shah (Whole-time Director), Hans Kaushik Kumar Shah (Whole Time Director & CFO), Nehal Babu Kareliya (Director), Pooja (Independent Director), Sourabh Ajmera (Independent Director), and Meenal Ajmera (Company Secretary & Compliance Officer).

As of March 2023, the management team of Hemant Surgical includes the following individuals:<BR><BR>1. Hanskumar Shamji Shah - Chairman & Managing Director<BR>2. Hemant Praful Shah - Whole-time Director<BR>3. Hans Kaushik Kumar Shah - Whole Time Director & CFO<BR>4. Nehal Babu Kareliya - Director<BR>5. Pooja - Independent Director<BR>6. Sourabh Ajmera - Independent Director<BR>7. Meenal Ajmera - Company Secretary & Compliance Officer<BR><BR>These members play various roles within the company, contributing to its governance and operational management.

What is the technical trend for Hemant Surgical?

As of June 3, 2025, Hemant Surgical's trend has shifted to bearish, driven by daily moving averages and Bollinger Bands indicating bearish momentum, despite a mildly bullish MACD signal on the weekly chart.

As of 3 June 2025, the technical trend for Hemant Surgical has changed from mildly bearish to bearish. The current stance is bearish with moderate strength, primarily driven by the daily moving averages indicating bearish momentum and the Bollinger Bands showing a bearish signal on both weekly and monthly time frames. The Dow Theory also supports a mildly bearish outlook on the weekly and monthly charts. While the MACD shows a mildly bullish signal on the weekly, it is not strong enough to counter the overall bearish indicators. The stock has underperformed significantly against the Sensex over multiple time frames, further reinforcing the bearish sentiment.

When is the next results date for Hemant Surgical?

No Upcoming Board Meetings

Has Hemant Surgical declared dividend?

No Dividend History Available